Want to see HK:2196 full AI Analyst Report?
2196 Stock Chart & Stats
HK$19.63
-HK$0.04(-0.30%)
At close: 4:00 PM EST
HK$19.63
-HK$0.04(-0.30%)
Day’s Range― - ―
52-Week RangeHK$14.90 - HK$29.00
Previous CloseN/A
Volume1.35M
Average Volume (3M)8.63M
Market Cap
HK$68.07B
Enterprise ValueHK$84.21K
Total Cash (Recent Filing)HK$15.29B
Total Debt (Recent Filing)HK$31.86B
Price to Earnings (P/E)18.2
Beta1.11
Next Earnings
Aug 26, 2026EPS Estimate
0.41Next Dividend Ex-DateN/A
Dividend Yield2.73%
Share Statistics
EPS (TTM)1.61
Shares Outstanding551,940,500
10 Day Avg. Volume5,166,409
30 Day Avg. Volume8,626,817
Financial Highlights & Ratios
PEG Ratio0.74
Price to Book (P/B)0.95
Price to Sales (P/S)1.15
P/FCF Ratio60.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$25.23Price Target Upside28.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
EPS Forecast (FY)1.47
Revenue Forecast (FY)HK$43.46B
Bulls Say, Bears Say
Bulls Say
Strong TTM Revenue ReboundA +158.4% TTM revenue rebound represents a durable recovery in demand and market traction across product lines. Sustained higher top-line growth improves scale economics, funds R&D and commercialization, and rebuilds channel leverage, supporting medium-term strategic initiatives.
Diversified Multi-segment ModelThe company's mix across manufacturing, distribution and healthcare services reduces single-channel risk and smooths cyclical swings. Structural diversification enables cross-selling, stable cash inflows from distribution margins, and resilience to policy or demand shocks in any one segment.
Solid Margins And Operating Cash GenerationHigh gross margin (~49%) and positive operating cash flow (~4.06B) indicate durable core profitability and operating leverage. Recent positive FCF shows improving cash generation capacity versus prior deficits, supporting reinvestment and execution of medium-term product commercialization plans.
Bears Say
Weak Cash Conversion And Volatile FCFFree cash flow equaling ~24% of net income and a history of volatility mean earnings do not reliably convert to cash. This constrains capital allocation flexibility, limits sustainable dividends or rapid deleveraging, and raises execution risk if working capital or capex needs rise.
Moderate Leverage With Average ReturnsA debt-to-equity around 0.75 combined with only ~7% ROE implies mid-level financial leverage and modest capital returns. That profile increases fixed interest obligations and reduces capacity to fund large investments without raising leverage or diluting returns to shareholders over the medium term.
Operating Profitability PressureRelatively low EBIT (~7.3%) and a declining EBITDA margin versus prior years point to cost pressure or adverse product mix. Persistent margin erosion would weaken cash flow resilience, hamper reinvestment in higher-margin products, and limit improvement in return metrics over the next several quarters.
Shanghai Fosun Pharmaceutical (Group) Co News
2196 FAQ
What was Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price range in the past 12 months?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H lowest stock price was HK$14.90 and its highest was HK$29.00 in the past 12 months.
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s market cap is HK$68.07B.
When is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s upcoming earnings report date is Aug 26, 2026 which is in 35 days.
How were Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s earnings last quarter?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H released its earnings results on Apr 28, 2026. The company reported HK$0.382 earnings per share for the quarter, beating the consensus estimate of HK$0.377 by HK$0.006.
Is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H overvalued?
According to Wall Street analysts Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price is currently Undervalued.
Does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pay dividends?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H pays a Annually dividend of HK$0.45 which represents an annual dividend yield of 2.73%. See more information on Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H dividends here
What is Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s EPS estimate is 0.41.
How many shares outstanding does Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H have?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H has 551,940,500 shares outstanding.
What happened to Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H’s price movement after its last earnings report?
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H reported an EPS of HK$0.382 in its last earnings report, beating expectations of HK$0.377. Following the earnings report the stock price went up 1.272%.
Which hedge fund is a major shareholder of Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H?
Currently, no hedge funds are holding shares in HK:2196
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shanghai Fosun Pharmaceutical (Group) Co Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
102.70%
12-Months-Change
Fundamentals
Return on Equity
2.73%
Trailing 12-Months
Asset Growth
9.40%
Trailing 12-Months
Company Description
Shanghai Fosun Pharmaceutical (Group) Co Ltd Class H
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a comprehensive healthcare enterprise, operating across Mainland China and international markets. Its principal activities include the research, development, production, and commercialization of pharmaceutical products. The company focuses on significant therapeutic domains such as oncology, immunology, metabolic disorders, gastrointestinal health, and central nervous system conditions. In addition to its drug offerings, Fosun Pharma provides medical devices and diagnostic solutions. Its multifaceted operations are organized into five key segments: pharmaceutical manufacturing, medical devices and diagnostics, healthcare services, pharmaceutical distribution and retail, and other business initiatives. This scope extends to managing healthcare facilities and hospitals, as well as the wholesale and retail distribution of medicines. The company was founded in 1994 and is headquartered in Shanghai, China.
2196 Stock 12 Month Forecast
Average Price Target
HK$25.23
▲(28.54% Upside)
Technical Analysis
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Livzon Pharmaceutical Group
―
China Resources Pharmaceutical Group Ltd.
―
Hansoh Pharmaceutical Group Company Limited
―